Geode Capital Management LLC raised its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 46.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 129,145 shares of the pharmaceutical company’s stock after buying an additional 40,858 shares during the period. Geode Capital Management LLC’s holdings in GlaxoSmithKline PLC were worth $5,444,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Azimuth Capital Management LLC raised its stake in shares of GlaxoSmithKline PLC by 4.0% in the first quarter. Azimuth Capital Management LLC now owns 75,309 shares of the pharmaceutical company’s stock valued at $3,175,000 after buying an additional 2,900 shares during the period. Cambridge Investment Research Advisors Inc. raised its stake in shares of GlaxoSmithKline PLC by 4.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 111,308 shares of the pharmaceutical company’s stock valued at $4,693,000 after buying an additional 5,025 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 2,359 shares during the period. Mackenzie Financial Corp acquired a new stake in shares of GlaxoSmithKline PLC during the first quarter valued at about $202,000. Finally, Columbus Hill Capital Management L.P. acquired a new stake in shares of GlaxoSmithKline PLC during the first quarter valued at about $4,975,000. Institutional investors own 8.96% of the company’s stock.

GlaxoSmithKline PLC (GSK) traded up 0.2833% during trading on Friday, hitting $39.0102. 599,485 shares of the stock traded hands. The stock has a market cap of $95.34 billion, a P/E ratio of 37.7275 and a beta of 1.03. The stock has a 50 day moving average price of $41.99 and a 200-day moving average price of $41.84. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.59.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The firm had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, analysts anticipate that GlaxoSmithKline PLC will post $2.85 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a $0.491 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 5.05%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 197.00%.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/geode-capital-management-llc-acquires-40858-shares-of-glaxosmithkline-plc-nysegsk/1475135.html.

GSK has been the subject of a number of recent analyst reports. TheStreet lowered shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. Finally, Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and a consensus price target of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.